Department of Pharmacy, China Medical University, Taichung, Taiwan, Republic of China.
Department of Pharmacy, China Medical University Beigang Hospital, Yunlin County, Taiwan, Republic of China.
Lipids Health Dis. 2020 Nov 3;19(1):232. doi: 10.1186/s12944-020-01412-6.
In the recent years, chronic obstructive pulmonary disease (COPD) has been found to be associated with a higher risk of new-onset osteoporotic fracture (NOF). However, the existence of such an association in the COPD patients receiving statin treatment remains unknown. The present study aimed to investigate the association between COPD and NOF in statin-treated patients.
The present study was conducted over a period of 10 years (January 2004 to December 2013) in Taiwan. COPD patients receiving statin treatment were included in the statin user group, whereas the randomly selected statin non-users, with 1:1 matching for sex, age, index date, and Charlson Comorbidity Index, were included in the statin non-user group. The hazard ratio (HR) of NOFs in COPD patients was estimated between statin user and non-user groups.
A total of 86,188 cases were identified as the statin-treated patients, and 86,188 subjects were included in the control group of statin non-users. Initially, the risk of NOF was found to be higher among the statin users as compared to non-users [HR, 1.12; 95% confidence interval (CI), 1.01-1.25]. However, the calculation of risk for NOFs after the adjustment for age, sex, comorbidities, and concurrent medications indicated no association of NOF (HR, 0.81; 95% CI, 0.55-1.21) with COPD in patients receiving statin treatment as compared to statin non-users.
The results of the study provided first evidence for the absence of any association between COPD and NOFs in statin-treated patients during a follow-up period of 10 years. Thus, the findings of this study might support the hypothesis stating the potent pleiotropic effects of statins. In clinical practice, these drugs might prove beneficial for the patients with COPD.
近年来,慢性阻塞性肺疾病(COPD)与新发骨质疏松性骨折(NOF)的风险增加有关。然而,在接受他汀类药物治疗的 COPD 患者中,这种相关性是否存在尚不清楚。本研究旨在探讨 COPD 与他汀类药物治疗患者中 NOF 的相关性。
本研究在台湾进行了 10 年(2004 年 1 月至 2013 年 12 月)。接受他汀类药物治疗的 COPD 患者被纳入他汀类药物使用者组,而随机选择的、性别、年龄、指数日期和 Charlson 合并症指数与之匹配的他汀类药物非使用者被纳入他汀类药物非使用者组。使用 Cox 比例风险回归模型评估 COPD 患者发生 NOF 的风险比(HR)。
共确定了 86188 例他汀类药物治疗患者,其中 86188 例患者被纳入他汀类药物非使用者对照组。最初,与非使用者相比,他汀类药物使用者发生 NOF 的风险更高[HR,1.12;95%置信区间(CI),1.01-1.25]。然而,在校正年龄、性别、合并症和同时使用的药物后,计算 NOF 的风险表明,与他汀类药物非使用者相比,接受他汀类药物治疗的患者中 COPD 与 NOF 之间没有关联(HR,0.81;95%CI,0.55-1.21)。
本研究结果提供了在 10 年随访期间,他汀类药物治疗患者中 COPD 与 NOF 之间无关联的首次证据。因此,本研究的结果可能支持他汀类药物具有潜在的多效性作用的假设。在临床实践中,这些药物可能对 COPD 患者有益。